Associated Papers
Efficacy of TKIs in non-small cell lung cancer with atypical EGFR p.L747P and p.L747S mutations.
Hu Q et al.
Frontiers in Oncology, 2026
Plasma-Based Genomic Features Influencing Outcomes of T790M-Positive Non-Small Cell Lung Cancer Receiving Osimertinib.
Liu H et al.
Cancer Medicine, 2025
Rare mutations at EGFR L747 position: molecular characteristics and superior response to afatinib in NSCLC patients.
Huang Y et al.
Esmo Open, 2025
Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers.
Li K et al.
Clinical Medicine Insights. Oncology, 2024
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases.
Zhang L et al.
Frontiers in Oncology, 2022
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
Wang Y et al.
Bmc Cancer, 2021
Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study.
Lv C et al.
Journal of Thoracic Disease, 2020
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.
Lin G et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2020
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J et al.
Plos One, 2020
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer.
Coco S et al.
Cancers, 2019
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A et al.
International Journal of Molecular Sciences, 2019
Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
Tong L et al.
Theranostics, 2019
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q et al.
Pathology Oncology Research : Por, 2018
Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W et al.
Scientific Reports, 2018
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Klughammer B et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.
Vanni I et al.
International Journal of Molecular Sciences, 2015
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
Kaneda T et al.
Lung Cancer (amsterdam, Netherlands), 2014
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D et al.
Cellular Oncology (dordrecht, Netherlands), 2014
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.
Paz-Ares L et al.
Journal of Cellular and Molecular Medicine, 2014
EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.
Fang S et al.
Drug Design, Development and Therapy, 2014
EGFR mutation status in brain metastases of non-small cell lung carcinoma.
Burel-Vandenbos F et al.
Journal of Neuro-oncology, 2013
Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA.
Nakamura T et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2012
Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.
Takamochi K et al.
Lung Cancer (amsterdam, Netherlands), 2012
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K et al.
Journal of Clinical Pathology, 2012
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.
Taniguchi K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma.
Nakamura H et al.
Anticancer Research, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Pirker R et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2010
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
Kalikaki A et al.
Lung Cancer (amsterdam, Netherlands), 2010
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T et al.
Bmc Cancer, 2008
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma.
Wu SG et al.
The European Respiratory Journal, 2008
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A et al.
British Journal of Cancer, 2008
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Miyazawa H et al.
Cancer Science, 2008
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
Pallis AG et al.
British Journal of Cancer, 2007
Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
Sakuma Y et al.
American Journal of Clinical Pathology, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Engelman JA et al.
Science (new York, N.y.), 2007
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Zhang X et al.
Journal of Medical Genetics, 2007
Epidermal growth factor receptor mutations in lung cancer.
Sharma SV et al.
Nature Reviews. Cancer, 2007
Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.
Tanaka T et al.
Cancer Science, 2007
Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.
Oshita F et al.
British Journal of Cancer, 2006
Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
Suzuki E et al.
Japanese Journal of Clinical Oncology, 2006
Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.
Haneda H et al.
Lung Cancer (amsterdam, Netherlands), 2006
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
Jänne PA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
Niho S et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2006